Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PVLA Palvella Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: PVLA
Price (delayed)
$23.81
Market cap
$263.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.68
Enterprise value
$187.61M
Highlights
Palvella Therapeutics's quick ratio has soared by 172% YoY and by 21% from the previous quarter
The company's gross profit has surged by 97% YoY
Palvella Therapeutics's equity has surged by 153% YoY but it has decreased by 11% QoQ
The EPS has plunged by 134% YoY but it has grown by 40% from the previous quarter
The net income has dropped by 171% year-on-year and by 19% since the previous quarter
Key stats
What are the main financial stats of PVLA
Market
Valuations
Earnings
Shares outstanding
11.06M
Market cap
$263.24M
Enterprise value
$187.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.72
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
-$53,000
Gross profit
-$53,000
Operating income
-$16.66M
Net income
-$20.73M
EBIT
-$15.2M
EBITDA
-$15.17M
Free cash flow
-$8.29M
Per share
Balance sheet
Liquidity
EPS
-$4.68
EPS diluted
-$4.68
Free cash flow per share
-$0.75
Book value per share
$5.04
Revenue per share
$0
TBVPS
$7.21
Total assets
$79.44M
Total liabilities
$23.86M
Debt
$0
Equity
$55.58M
Working capital
$70.46M
Debt to equity
0
Current ratio
8.84
Quick ratio
8.42
Net debt/EBITDA
4.99
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.9%
Return on equity
-54.1%
Return on invested capital
N/A
Return on capital employed
-21.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PVLA stock price
How has the Palvella Therapeutics stock price performed over time
Intraday
-2.58%
1 week
-0.08%
1 month
-2.66%
1 year
N/A
YTD
98.42%
QTD
-14.93%
Financial performance
How have Palvella Therapeutics's revenue and profit performed over time
Revenue
-$53,000
Gross profit
-$53,000
Operating income
-$16.66M
Net income
-$20.73M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 171% year-on-year and by 19% since the previous quarter
The company's gross profit has surged by 97% YoY
The revenue has soared by 97% YoY
The operating income has contracted by 18% from the previous quarter
Price vs fundamentals
How does PVLA's price correlate with its fundamentals
Growth
What is Palvella Therapeutics's growth rate over time
Valuation
What is Palvella Therapeutics stock price valuation
P/E
N/A
P/B
4.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 134% YoY but it has grown by 40% from the previous quarter
Palvella Therapeutics's equity has surged by 153% YoY but it has decreased by 11% QoQ
PVLA's P/B is 136% above its last 4 quarters average of 2.0 and 52% above its 5-year quarterly average of 3.1
The revenue has soared by 97% YoY
Efficiency
How efficient is Palvella Therapeutics business performance
Palvella Therapeutics's ROA has plunged by 163% YoY but it has increased by 9% from the previous quarter
PVLA's return on equity has dropped by 109% year-on-year but it is up by 7% since the previous quarter
Dividends
What is PVLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PVLA.
Financial health
How did Palvella Therapeutics financials performed over time
Palvella Therapeutics's quick ratio has soared by 172% YoY and by 21% from the previous quarter
Palvella Therapeutics's total assets has soared by 169% YoY but it has decreased by 10% from the previous quarter
The debt is 100% lower than the equity
Palvella Therapeutics's equity has surged by 153% YoY but it has decreased by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.